Sinopsis
Podcast by AUAUniversity
Episodios
-
Setting Up a Clinic In The Community Setting | The Role Of Chemotherapy Treatment
09/07/2019 Duración: 53minThis educational series is supported by independent educational grants from: AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme Episode 2: Setting Up and Managing Advanced Prostate Cancer in the Community Setting: Unique Challenges and the Role of Chemotherapy, Treatment Sequencing and Future Approaches CME Available: https://auau.auanet.org/node/25404 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists. To extend the educational reach, the AUA will capture the live presentations and develop three pod
-
AUA2019 037IC Help Patients Decide On Prostate Cancer Screening And Treatment
05/07/2019 Duración: 01h46minSupport provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/node/24579 Instructional Course Director(s) Danil Makarov, MD photo Danil Makarov, MD New York University School of Medicine Instructional Course Faculty(s) Michael Barry, MD Harvard Medical School Angela Fagerlin, MD Chair, Department of Population Health Sciences Shared Decision Making was recently accepted as the standard of care when counseling patients considering PSA screening by the US Preventative Services Taskforce. Shared Decision Making is also embedded into numerous recently published AUA guidelines (including the localized prostate cancer guideline). In spite of these clear recommendations, Shared Decision Making is not frequently used in clinical practice. We propose a course that would teach the essentials of Shared Decision Making (SDM) to practicing urologists who he
-
Genetic Testing in Advanced Prostate Cancer and Initial Management of Biochemical Recurrence
02/07/2019 Duración: 53minThis educational series is supported by independent educational grants from: AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme Episode 1: Genetic Testing in Advanced Prostate Cancer and the Identification of High Risk Disease and Initial Management of Biochemical Recurrence CME Available: https://auau.auanet.org/node/25403 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists. To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview
-
AUA2019 035IC Contemporary Pharmacotherapy For OAB 2019
27/06/2019 Duración: 01h54minSupport provided by an independent educational grant from Allergan, Astellas and Medtronic CME Available: https://auau.auanet.org/node/24584 Instructional Course Director(s) Eric Rovner, MD Medical University of South Carolina Instructional Course Faculty(s) Alan Wein, MD,PHD Founders Professor and Emeritus Chief of Urology and Director, Residency Program University of Pennsylvania Christopher Chapple, MD Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Sheffield Hallam University Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes. The publication of the recently updated AUA/SUFU Guideline entitled "Diagnosis and Treatment of
-
AUA2019 077IC Establishing A Multidisciplinary Oncology Clinic With Advanced Therapeutics
20/06/2019 Duración: 01h44minSupport provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/integrating-care-oncology-patients-establishing-multidisciplinary-oncology-clinic-advanced This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting. Participants will have a better understanding of the best timing for referrals to medical oncology with specific examples including hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, role of immunotherapy in advanced bladder and kidney cancer. The integratio
-
AUA2019 027IC AUA CRPC Guidelines And Therapeutic Advances In Metastatic Prostate Cancer
14/06/2019 Duración: 02h01minSupport provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/aua-castration-resistant-prostate-cancer-crpc-guidelines-and-therapeutic-advances-metastatic Instructional Course Director(s) Michael Cookson, MD, MMHC Professor and Chair University of Oklahoma Instructional Course Faculty(s) David Jarrard, MD University of Wisconsin Adam Kibel, MD Brigham Health, Harvard University William Lowrance, MD University of Utah, Huntsman Cancer Institute This course will review the important and newly updated 2018 AUA Guidelines on Castration-Resistant Prostate Cancer. This includes a thorough discussion of new trials and approval of agents for MO non-metastatic nmCRPC. In addition, we will review therapeutic breakthroughs in the management of advanced and metastatic hormone naïve prostate cancer (mHSPPC). Faculty will highlight the management of
-
AUA2019 023IC - Chemotherapy And Immunotherapy Options For Genitourinary Malignancies
06/06/2019 Duración: 01h49minSupport provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/chemo... Instructional Course Director(s) Costas Lallas, MD Thomas Jefferson University Hospital Instructional Course Faculty(s) Anne Calvaresi, DNP, CRNP Thomas Jefferson University Edouard Trabulsi, MD, FACS Sidney Kimmel Medical College at Thomas Jefferson University Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, prostate, and testis cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a question and answer period. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inh
-
AUA2019 076IC - Advanced OAB Therapies - What To Do When 1st And 2nd Line Therapies Do Not Work
30/05/2019 Duración: 01h58minSupport provided by an independent educational grant from Allergan, Astellas and Medtronic CME Available: https://auau.auanet.org/node/24581 Instructional Course Director(s) Kathleen Kobashi, MD, FACS, FPMRS Virginia Mason Medical Center Instructional Course Faculty(s) Sandip Vasavada, MD Professor of Surgery/Urology Cleveland Clinic Glickman Urological Institute and Lerner College of Medicine David Ginsberg, MD USC Institute of Urology This course would aim to discuss all guidelines-approved 3rd line therapies for the treatment of overactive bladder (OAB). Case–based discussion will be used adjunctively to illustrate how best to select patients in varying clinical scenarios and how to optimally counsel a patient on each of the available modalities, including onabotulinumtoxinA injection of the bladder, tibial nerve stimulation, and sacral nerve stimulation (SNS). Emerging therapies in neuromodulation will also be introduced. Optimal patient selection and integration of these therapies into the urolog
-
AUA2019 013IC Genetic Testing In Prostate Cancer
21/05/2019 Duración: 01h57minSupport provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/node/24582 Instructional Course Director(s) Todd Morgan, MD University of Michigan Instructional Course Faculty(s) Leonard Gomella, MD,FACS Professor And Chair Thomas Jefferson University Heather Cheng, MD, PhD University of Washington There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g. PARP inhibition), Urologists are suddenly being confronted with questions surrounding screening guidelines in men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment deci
-
Live From AUA2019 Management Of Advanced And Metastatic Urothelial Carcinoma
16/05/2019 Duración: 55minThis educational activity is supported by independent educational grants from: Astellas, Merck and Seattle Genetics CME Available: https://auau.auanet.org/node/24777 In this unique presentation, panelists at the 2019 AUA Annual Meeting cover the management of advanced and metastatic urothelial carcinoma while discussing key take-home messages from AUA2019 sessions. Moderator: Kristen R. Scarpato, MD, MPH, Vanderbilt University Medical Center Faculty: Anne E. Calvaresi, DNP, CRNP, RNFA, Thomas Jefferson University Siamak Daneshmand, MD, University of Southern California/Norris Comprehensive Cancer Center Anthony C. Wong, MD, PhD, University of California, San Francisco
-
Live From AUA2019 Management Of Non - Muscle Invasive Urothelial Carcinoma
08/05/2019 Duración: 51minThis educational activity is supported by independent educational grants from: Astellas, Merck and Seattle Genetics CME Available: https://auau.auanet.org/node/24288 In this unique presentation, panelists at the 2019 AUA Annual Meeting cover the management of non-muscle invasive urothelial carcinoma while discussing key take-home messages from AUA2019 sessions. Moderator: Kristen R. Scarpato, MD, MPH, Vanderbilt University Medical Center Faculty: John L. Gore, MD, MS, FACS, University of Washington Sima P. Porten, MD, MPH, FACS, University of California, San Francisco Chad R. Ritch, MD, MBA, University of Miami
-
Medical Student Webinar: Urologic Care within Transgender Medicine: Overview of Core Knowledge
11/04/2019 Duración: 01h18minThe American Urological Association in conjunction with the National Medical Student Education Curriculum Committee is proud to sponsor a free podcast that will provide exposure to the core concepts and terminology underlying the care urologists provide within Transgender Medicine. This webinar will provide an overview of this complex discipline, and is designed to give medical students the ability to engage in thoughtful discourse with colleagues when caring for this patient population. It will also provide specific insight into the ways Urology is emerging as a leading specialty in this discipline, paving the way for optimization of lifelong care, including before and after surgical reconstruction.
-
Framing Pragmatic Strategies To Reduce Mortality From Urothelial Cancer
25/03/2019 Duración: 26minCo Host: Ralph W. de Vere White M.D.
-
Successful Utilization of Advanced Practice Providers in Urology Practice
15/03/2019 Duración: 44minSuccessful Utilization of Advanced Practice Providers in Urology Practice by AUAUniversity
-
Court is in Session: Benign: Opioid overdose in patient with chronic flank pain
27/02/2019 Duración: 50minDefendant(s) Arthur Smith, MD Hofstra University Moderator(s) Deborah Lightner, MD Mayo Clinic Expert Witness (Defense)(s) Glenn Preminger, MD Professor and Chief Duke University Medical Center Expert Witness (Plaintiff)(s) Gregory Auffenberg, MD, MS Memorial Sloan Kettering Cancer Center
-
AUA2018 Second Opinion Cases (ask the Guidelines!): Benign Prostatic Hyperplasia (BPH)
12/02/2019 Duración: 27minModerator(s) Kevin McVary, MD Southern Illinois University School of Medicine Panelist(s) Harris Foster, Jr., MD Yale University School of Medicine Charles Welliver, MD Albany Medical College Steven Kaplan, MD Icahn School of Medicine at Mount Sinai
-
AUA2018 Second Opinion Cases Testosterone Deficiency
31/01/2019 Duración: 32minSecond Opinion Cases (Ask the Guidelines!): Testosterone Deficiency Moderator(s) John Mulhall, MD Memorial Sloan Kettering Cancer Center Panelist(s) Robert Brannigan, MD Northwestern University, Feinberg School of Medicine Landon Trost, MD Mayo Clinic Emily Kurtz, MD Vanderbilt University Medical Center
-
AUA2018 Second Opinion Cases Erectile Dysfunction
23/01/2019 Duración: 26minAUA2018 Second Opinion Cases in Erectile Dysfunction Moderator(s) Lawrence Hakim, MD, FACS Panelist(s) Arthur Burnett, MD, MBA, FACS Christian Nelson, PhD Alan Shindel, MD, MAS
-
AUA2018 Take Home Messages Bladder Cancer - Basic Science Malignant
07/01/2019 Duración: 18minAUA2018 Take Home Messages Bladder Cancer - Basic Science Malignant by AUAUniversity
-
AUA2018 Take Home Messages Kidney Cancer & Transplantation
03/01/2019 Duración: 14minAUA2018 Take Home Messages Kidney Cancer & Transplantation by AUAUniversity